» Articles » PMID: 12489060

Serum Plant Sterols As a Potential Risk Factor for Coronary Heart Disease

Overview
Journal Metabolism
Specialty Endocrinology
Date 2002 Dec 19
PMID 12489060
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

In patients with the inherited disease of phytosterolemia, elevated concentrations of plant sterols (eg, campesterol and sitosterol) have been implicated as a risk factor for premature atherosclerosis. Whether plasma concentrations of campesterol and sitosterol are risk factors for coronary heart disease (CHD) in nonphytosterolemia subjects has not been established. Therefore, the present study examined the role of plant sterols in patients admitted for elective artery coronary bypass graft (ACBG). Serum concentrations of campesterol and sitosterol, as well as lathosterol, desmosterol, cholestanol, and lipoproteins were analyzed in 42 men and 11 women without lipid-lowering treatment during the past. Twenty-six patients reported a positive family history in their first-degree relatives for CHD. Lipid profile and other risk factors were comparable in both groups. Patients with a positive family history for CHD had significant higher plasma levels of campesterol (.50 +/-.17 v.38 +/-.16 mg/dL; P =.011), sitosterol (.40 +/-.11 v.31 +/-.11 mg/dL; P =.004) and their ratios to cholesterol. Lathosterol, desmosterol, cholestanol, and their ratios to cholesterol were not significantly different. Analysis of covariance (ANCOVA) analysis showed no influence of sex, age, triglycerides, total-, low-density lipoprotein (LDL)-, and high-density lipoprotein (HDL)-cholesterol on the results, but confirmed a strong influence of plant sterols. These findings support the hypothesis that plant sterols might be an additional risk factor for CHD.

Citing Articles

Phytosterol-Enriched Dietary Supplements for Lowering Plasma LDL-Cholesterol: Yes or No?.

Stellaard F, Lutjohann D Nutrients. 2025; 17(4).

PMID: 40004982 PMC: 11858453. DOI: 10.3390/nu17040654.


Plant Sterols and Plant Stanols in Cholesterol Management and Cardiovascular Prevention.

Barkas F, Bathrellou E, Nomikos T, Panagiotakos D, Liberopoulos E, Kontogianni M Nutrients. 2023; 15(13).

PMID: 37447172 PMC: 10343346. DOI: 10.3390/nu15132845.


Efficacy and Safety of Pitavastatin/Ezetimibe Fixed-Dose Combination vs. Pitavastatin: Phase III, Double-Blind, Randomized Controlled Trial.

Tsujita K, Yokote K, Ako J, Tanigawa R, Tajima S, Suganami H J Atheroscler Thromb. 2023; 30(11):1580-1600.

PMID: 36908150 PMC: 10627746. DOI: 10.5551/jat.64006.


Phytosterols and Cardiovascular Disease.

Makhmudova U, Schulze P, Lutjohann D, Weingartner O Curr Atheroscler Rep. 2021; 23(11):68.

PMID: 34468867 PMC: 8410723. DOI: 10.1007/s11883-021-00964-x.


Baseline low-density lipoprotein cholesterol predicts the benefit of adding ezetimibe on statin in statin-naïve acute coronary syndrome.

Im J, Kawada-Watanabe E, Yamaguchi J, Arashi H, Otsuki H, Matsui Y Sci Rep. 2021; 11(1):7480.

PMID: 33820931 PMC: 8021554. DOI: 10.1038/s41598-021-87098-x.